Cancer stem cells in surgery, Gastroenterol, vol.35, pp.2603-2611, 2013. ,
CD133: a stem cell biomarker and beyond, Exp Hematol Oncol, vol.2, p.17, 2013. ,
Promoter hypomethylation regulates CD133 expression in human gliomas, Cell Res, vol.18, pp.1037-1046, 2008. ,
Nomenclature of prominin-1 (CD133) splice variants -an update, Tissue Antigens, vol.69, pp.602-606, 2007. ,
AC133-2, a novel isoform of human AC133 stem cell antigen, J Biol Chem, vol.277, pp.20711-20716, 2002. ,
CD133: to be or not to be, is this the real question?, Am J Transl Res, vol.5, pp.563-581, 2013. ,
Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells, Reprod Biol Endocrinol, vol.8, p.147, 2010. ,
Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target, Stem Cells Transl Med, vol.4, pp.1033-1043, 2015. ,
The biology and role of CD44 in cancer progression: therapeutic implications, J Hematol Oncol, vol.11, p.64, 2018. ,
Prognostic significance of CD44 in human colon cancer and gastric cancer: Evidence from bioinformatic analyses, Oncotarget, vol.7, pp.45538-45546, 2016. ,
CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis, Cell Stem Cell, vol.14, pp.342-356, 2014. ,
Prognostic Significance of CD44v6, CD133, CD166, and ALDH1 Expression in Small Intestinal Adenocarcinoma, Appl Immunohistochem Mol Morphol, vol.23, pp.682-688, 2015. ,
Stem cell CD44v isoforms promote intestinal cancer formation in Apc(min) mice downstream of Wnt signaling, Oncogene, vol.33, pp.665-670, 2014. ,
Promoter-and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by methyl-CpG binding proteins and histone modifications, BMC Cancer, vol.10, p.297, 2010. ,
Histone H3 lysine 9 trimethylation and HP1? favor inclusion of alternative exons, Nat Struct Mol Biol, vol.18, pp.337-344, 2011. ,
ALCAM/CD166: cancer-related issues, Cancer Genomics Proteomics, vol.7, pp.231-243, 2010. ,
Phenotypic characterization of human colorectal cancer stem cells, Proc Natl Acad Sci, vol.104, pp.10158-10163, 2007. ,
Molecular identification and targeting of colorectal cancer stem cells, Oncotarget, vol.1, pp.387-395, 2010. ,
Molecular isolation and characterization of a soluble isoform of activated leukocyte cell adhesion molecule that modulates endothelial cell function, J Biol Chem, vol.279, pp.55315-55323, 2004. ,
Mechanisms of transcriptional regulation and prognostic significance of activated leukocyte cell adhesion molecule in cancer, Mol Cancer, vol.9, p.266, 2010. ,
Aberrant DNA methylation in ovarian cancer: is there an epigenetic predisposition to drug response?, Ann N Y Acad Sci, vol.983, pp.243-250, 2003. ,
The role of epigenetic therapies in colorectal cancer, Curr Probl Cancer, vol.42, pp.530-547, 2018. ,
The future of epigenetic therapy in solid tumours--lessons from the past, Nat Rev Clin Oncol, vol.10, pp.256-266, 2013. ,
Biological and therapeutic impact of intratumor heterogeneity in cancer evolution, Cancer Cell, vol.27, pp.15-26, 2015. ,
In vitro models of cancer stem cells and clinical applications, BMC Cancer, vol.16, p.738, 2016. ,
Harnessing the potential of epigenetic therapy to target solid tumors, J Clin Invest, vol.124, pp.56-63, 2014. ,
Poised epigenetic states and acquired drug resistance in cancer, Nat Rev Cancer, vol.14, pp.747-753, 2014. ,
Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells, PLoS One, vol.12, p.176139, 2017. ,
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents, Clin Cancer Res, vol.19, pp.657-667, 2013. ,
The identification and validation of Trichosstatin A as a potential inhibitor of colon tumorigenesis and colon cancer stem-like cells, Am J Cancer Res, vol.7, pp.1227-1237, 2017. ,
GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer, Epigenetics, vol.12, pp.540-550, 2017. ,
LinkedOmics: analyzing multi-omics data within and across 32 cancer types, Nucleic Acids Res, vol.46, pp.956-963, 2018. ,
Bromodomain inhibitors and cancer therapy: From structures to applications, Epigenetics, vol.12, pp.323-339, 2017. ,
SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis, PLoS One, vol.8, p.74250, 2013. ,
Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study, Oncotarget, vol.8, pp.35326-35338, 2017. ,
A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies, Cancer Chemother Pharmacol, vol.69, pp.547-554, 2012. ,
Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin, Oncotarget, vol.7, pp.67495-67506, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02298775
A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer, Invest New Drugs, vol.18, pp.83-91, 2000. ,
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors, J Clin Oncol, vol.25, pp.4603-4609, 2007. ,
A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt), KRAS metastatic colorectal cancer. Invest New Drugs, vol.31, pp.1257-1264, 2013. ,
Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer, Oncotarget, vol.7, pp.16158-16171, 2016. ,
Zebularine inhibits tumorigenesis and stemness of colorectal cancer via p53-dependent endoplasmic reticulum stress, Sci Rep, vol.3, p.3219, 2013. ,
Peptide inhibition of the SETD6 methyltransferase catalytic activity, Oncotarget, vol.9, pp.4875-4885, 2017. ,
Discovery of Potent and Selective Allosteric Inhibitors of Protein Arginine Methyltransferase 3 (PRMT3), J Med Chem, vol.61, pp.1204-1217, 2018. ,
Structural basis of arginine asymmetrical dimethylation by PRMT6, Biochem J, vol.473, pp.3049-3063, 2016. ,
A novel histone acetyltransferase inhibitor modulating Gcn5 network: cyclopentylidene-[4-(4'-chlorophenyl)thiazol-2-yl)hydrazone, J Med Chem, vol.52, pp.530-536, 2009. ,
Chemical inhibition of the histone acetyltransferase activity in Arabidopsis thaliana, Biochem Biophys Res Commun, vol.483, pp.664-668, 2017. ,
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers, Cancer Chemother Pharmacol, vol.73, pp.495-501, 2014. ,
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study, J Clin Oncol, vol.25, pp.1979-1985, 2007. ,
Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours, Br J Cancer, vol.106, pp.77-84, 2012. ,
A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors, Invest New Drugs, vol.33, pp.225-232, 2015. ,
Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors, Cancer Chemother Pharmacol, vol.70, pp.251-258, 2012. ,
,
combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study, Lancet Oncol, vol.11, pp.459-464, 2010. ,
A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy, Cancer Chemother Pharmacol, vol.65, pp.979-988, 2010. ,
A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer, Cancer Chemother Pharmacol, vol.69, pp.743-751, 2012. ,
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker, Br J Cancer, vol.101, pp.1044-1050, 2009. ,
A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors, Invest New Drugs, vol.32, pp.323-329, 2014. ,
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336), Invest New Drugs, vol.27, pp.469-475, 2009. ,
Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors, Cancer Invest, vol.22, pp.886-896, 2004. ,
, Clinical trials of resveratrol. Ann N Y Acad Sci, vol.1215, pp.161-169, 2011.
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells, J Med Chem, vol.55, pp.10937-10947, 2012. ,
Small molecule KDM4s inhibitors as anti-cancer agents, J Enzyme Inhib Med Chem, vol.33, pp.777-793, 2018. ,
Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications, Curr Med Chem, vol.17, pp.190-197, 2010. ,
Bufalin Inhibits HCT116 Colon Cancer Cells and Its Orthotopic Xenograft Tumor in Mice Model through Genes Related to Apoptotic and PTEN/AKT Pathways, Gastroenterol Res Pract, p.457193, 2015. ,
Histone acetyltransferases: challenges in targeting bi-substrate enzymes, Clin Epigenetics, vol.8, p.59, 2016. ,
Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer, Cancer Med, vol.7, pp.5382-5393, 2018. ,
Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat, Eur J Med Chem, vol.158, pp.593-619, 2018. ,
Biotinyl-methyl 4-(amidomethyl)benzoate is a competitive inhibitor of human biotinidase, J Nutr Biochem, vol.19, pp.826-832, 2008. ,
Discovery of a PCAF Bromodomain Chemical Probe, Angew Chem Int Ed Engl, vol.56, pp.827-831, 2017. ,
The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex, Nat Chem Biol, vol.13, pp.389-395, 2017. ,